Natixis Sage Therapeutics, Inc. Transaction History

Natixis

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$18.62 - $26.95 $575,451 - $832,889	-30,905 Reduced 99.69%	95 $1,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $519,250 - $1.52 Million	31,000 New	31,000 $637,000
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $968,704 - $1.34 Million	35,200 New	35,200 $1.14 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $1.29 Million - $1.64 Million	-34,900 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $1.41 Million - $2 Million	34,900 New	34,900 $1.55 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.